Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations

被引:0
作者
Li-Chan Tao
Jia-ni Xu
Ting-ting Wang
Fei Hua
Jian-Jun Li
机构
[1] The Third Affiliated Hospital of Soochow University,State Key Laboratory of Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases
[2] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
来源
Cardiovascular Diabetology | / 21卷
关键词
Triglyceride-glucose index; Insulin resistance; Cardiovascular disease;
D O I
暂无
中图分类号
学科分类号
摘要
The triglyceride-glucose (TyG) index has been identified as a reliable alternative biomarker of insulin resistance (IR). Recently, a considerable number of studies have provided robust statistical evidence suggesting that the TyG index is associated with the development and prognosis of cardiovascular disease (CVD). Nevertheless, the application of the TyG index as a marker of CVD has not systemically been evaluated, and even less information exists regarding the underlying mechanisms associated with CVD. To this end, in this review, we summarize the history of the use of the TyG index as a surrogate marker for IR. We aimed to highlight the application value of the TyG index for a variety of CVD types and to explore the potential limitations of using this index as a predictor for cardiovascular events to improve its application value for CVD and provide more extensive and precise supporting evidence.
引用
收藏
相关论文
共 687 条
  • [1] Sacco RL(2016)The heart of 25 by 25: achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke: a modeling study from the American Heart Association and World Heart Federation Circulation 133 e674-690
  • [2] Roth GA(2019)Extreme atherosclerotic cardiovascular disease (ASCVD) risk recognition Curr Diab Rep 19 61-182
  • [3] Reddy KS(2019)The potential role of biomarkers associated with ASCVD risk: risk-enhancing biomarkers J Lipid Atheroscler 8 173-212
  • [4] Arnett DK(2019)Epidemiology of cardiovascular disease in China: current features and implications Nat Rev Cardiol 16 203-795
  • [5] Bonita R(2009)Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 773-537
  • [6] Gaziano TA(2019)Myocardial mechano-energetic efficiency and insulin resistance in non-diabetic members of the strong heart study cohort Cardiovasc Diabetol 18 56-304
  • [7] Heidenreich PA(2021)Insulin resistance, cardiovascular stiffening and cardiovascular disease Metabolism 119 529-199
  • [8] Huffman MD(2021)Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension J Clin Hypertens (Greenwich) 23 299-3351
  • [9] Mayosi BM(2008)The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects Metab Syndr Relat Disord 6 187-e100
  • [10] Mendis S(2019)Indirect insulin resistance detection: current clinical trends and laboratory limitations Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 163 3347-105